Rodman & Renshaw Initiates Coverage On Karyopharm Therapeutics with Buy Rating, Announces Price Target of $28
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. KPTI | 0.00 |
Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:
KPTI) with a Buy rating and announces Price Target of $28.
